Tiziana life sciences plc ("tiziana" or the "company") - aim delisting and admission to the standard listing segment of main market

New york and london, jan. 20, 2021 (globe newswire) -- tiziana life sciences plc (nasdaq: tlsa / aim: tils) (“tiziana” or the “company”), a biotechnology company focused on innovative therapeutics for oncology, inflammation, and infectious diseases, today provided a further update with respect to the cancellation of admission of its ordinary shares to trading on aim and admission to listing of its ordinary shares (the "ordinary shares") on the standard listing segment of the official list of the financial conduct authority ("fca") (the "official list") and admission to trading on the main market for listed securities (the "main market") of london stock exchange plc (the "london stock exchange") (together, "admission").
TLSA Ratings Summary
TLSA Quant Ranking